Research programme: colostrinin constituent peptides - ReGen Therapeutics

Drug Profile

Research programme: colostrinin constituent peptides - ReGen Therapeutics

Alternative Names: Colostinin

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Peptides
  • Mechanism of Action Amyloid beta-protein inhibitors; Antioxidants; Apoptosis inhibitors; Cell differentiation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (PO)
  • 01 Sep 2006 Early research in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top